HomeProductsBioactive CompoundsProtein Kinase Targetsc-KitAmuvatinib
Chemical structure of CAS 850879-09-3

Amuvatinib

CAS No.850879-09-3
MDL No.MFCD16038298
MFC23H21N5O3S
MW447.50
InChI KeyFOFDIMHVKGYHRU-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

N-(1,3-Benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide is an N-arylpiperazine.

CAS No.850879-09-3
Product NameAmuvatinib

Biological Targets

MET·PDGFRA·KIT·FLT3

Associated Conditions

neoplasm·small cell lung carcinoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Nature genetics • Vol. 44, Issue 8 • 2012
PMID: 22751098PMC: PMC3408577DOI: 10.1038/ng.2330

The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • Vol. 101, Issue 1 • 2011
PMID: 21903282DOI: 10.1016/j.radonc.2011.08.013

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells.

Radiation oncology (London, England) • Vol. 4 • 2009
PMID: 20028557PMC: PMC2806296DOI: 10.1186/1748-717X-4-69

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.

Oncogene • Vol. 26, Issue 27 • 2007
PMID: 17325667DOI: 10.1038/sj.onc.1210173

Documentation